Prehabilitation and Immunonutrition in Pancreatic Cancer Therapy.

Roorbach M; Bleakley W; Russell MC

doi:10.1016/j.soc.2025.03.004

← 뒤로

Prehabilitation and Immunonutrition in Pancreatic Cancer Therapy.

Surgical oncology clinics of North America 2026 Vol.35(1) p. 55-69

Roorbach M, Bleakley W, Russell MC

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Pancreatic cancer is an aggressive disease with demanding therapies.

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Roorbach M, Bleakley W, Russell MC (2026). Prehabilitation and Immunonutrition in Pancreatic Cancer Therapy.. Surgical oncology clinics of North America, 35(1), 55-69. https://doi.org/10.1016/j.soc.2025.03.004

MLA Roorbach M, et al.. "Prehabilitation and Immunonutrition in Pancreatic Cancer Therapy.." Surgical oncology clinics of North America, vol. 35, no. 1, 2026, pp. 55-69.

PMID 41233073

DOI 10.1016/j.soc.2025.03.004

Abstract

Pancreatic cancer is an aggressive disease with demanding therapies. Patients often present physically and nutritionally debilitated and then are required to undergo rigorous chemotherapy and/or chemoradiation, as well as operative interventions. Ensuring that patients are physically, nutritionally, and psychosocially supported may promote tolerance of neoadjuvant treatments to ensure progression to and success of surgery.

MeSH Terms

Humans; Pancreatic Neoplasms; Immunotherapy; Preoperative Care; Neoadjuvant Therapy; Preoperative Exercise; Immunonutrition Diet